Enzon Pharma (ENZN) Ends Development of rhMBL, Announces Survivin Antagonist IND Accepted

February 10, 2009 8:26 AM EST Send to a Friend
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced the discontinuation of the current recombinant human Mannose-Binding Lectin (rhMBL) clinical program, as it did not meet the criteria established for its continued development.

Sepertaly, Enzon announced the FDA accepted the Company's Investigational New Drug (IND) application for the use of its Survivin antagonist. The Company will open a Phase I study evaluating safety of the Survivin antagonist during the first quarter of 2009.

You May Also Be Interested In





Related Categories

FDA, Hot List

Add Your Comment